- Home
- NPKI vs PHAR Comparison
NPKI vs PHAR Comparison
Compare NPKI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPKI | PHAR |
|---|---|---|
| Founded | 1932 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NPKI | PHAR |
|---|---|---|
| Price | $12.10 | $17.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $14.17 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 661.0K | 24.5K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | 0.00 |
| Revenue | $259,372,000.00 | ★ $362,274,000.00 |
| Revenue This Year | $26.96 | $25.19 |
| Revenue Next Year | $13.16 | $4.47 |
| P/E Ratio | ★ $31.90 | $3,041.40 |
| Revenue Growth | 25.65 | ★ 26.78 |
| 52 Week Low | $4.76 | $7.50 |
| 52 Week High | $14.00 | $18.30 |
Technical Indicators
Market Signals| Indicator | NPKI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 49.54 |
| Support Level | $12.21 | $16.98 |
| Resistance Level | $12.57 | $18.30 |
| Average True Range (ATR) | 0.33 | 0.73 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 13.03 | 27.04 |
Price Performance
Historical ComparisonAbout NPKI NPK International Inc.
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.